EcoDrugPlus

Protein Mono-Adp-Ribosyltransferase Parp3-Like

Ensembl ID : ENSECRG00000016494
Gene Symbol: LOC114668791
3 Cross references
199 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSECRG00000011638
Gene Symbol: PPP3CA
3 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSECRG00000014902
Gene Symbol: PTK2
3 Cross references
245 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSECRG00000002266
Gene Symbol: PTK2B
3 Cross references
213 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSECRG00000020935
Gene Symbol: PTPN11
3 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSECRG00000012820
Gene Symbol: PTPRB
3 Cross references
266 Possible Orthologues:

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSECRG00000008215
Gene Symbol: LOC114659292
3 Cross references
174 Possible Orthologues:

Proteinase-Activated Receptor 3-Like

Ensembl ID : ENSECRG00000011786
Gene Symbol: LOC114660147
2 Cross references
117 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSECRG00000009959
Gene Symbol: P2RX3
3 Cross references
271 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSECRG00000007288
Gene Symbol: P2RY1
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSECRG00000007558
Gene Symbol: P2RY12
1 Cross references
182 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSECRG00000001636
Gene Symbol: P2RY2
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).